- Home
- CBL vs TSHA Comparison
CBL vs TSHA Comparison
Compare CBL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- TSHA
- Stock Information
- Founded
- CBL 1978
- TSHA 2019
- Country
- CBL United States
- TSHA United States
- Employees
- CBL N/A
- TSHA N/A
- Industry
- CBL Real Estate Investment Trusts
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CBL Real Estate
- TSHA Health Care
- Exchange
- CBL Nasdaq
- TSHA Nasdaq
- Market Cap
- CBL 777.7M
- TSHA 728.4M
- IPO Year
- CBL 1993
- TSHA 2020
- Fundamental
- Price
- CBL $31.13
- TSHA $2.84
- Analyst Decision
- CBL
- TSHA Strong Buy
- Analyst Count
- CBL 0
- TSHA 7
- Target Price
- CBL N/A
- TSHA $8.71
- AVG Volume (30 Days)
- CBL 98.6K
- TSHA 3.5M
- Earning Date
- CBL 11-10-2025
- TSHA 11-12-2025
- Dividend Yield
- CBL 5.76%
- TSHA N/A
- EPS Growth
- CBL 128.05
- TSHA N/A
- EPS
- CBL 2.10
- TSHA N/A
- Revenue
- CBL $539,452,000.00
- TSHA $8,098,000.00
- Revenue This Year
- CBL N/A
- TSHA N/A
- Revenue Next Year
- CBL N/A
- TSHA N/A
- P/E Ratio
- CBL $15.07
- TSHA N/A
- Revenue Growth
- CBL 2.20
- TSHA N/A
- 52 Week Low
- CBL $21.10
- TSHA $1.05
- 52 Week High
- CBL $33.54
- TSHA $3.40
- Technical
- Relative Strength Index (RSI)
- CBL 51.97
- TSHA 43.75
- Support Level
- CBL N/A
- TSHA $3.16
- Resistance Level
- CBL $32.69
- TSHA $2.99
- Average True Range (ATR)
- CBL 0.47
- TSHA 0.19
- MACD
- CBL -1.34
- TSHA -0.03
- Stochastic Oscillator
- CBL 95.24
- TSHA 8.94
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.